Targeting Plk1 Sensitizes Pancreatic Cancer to Immune Checkpoint Therapy

Area of Science:

• Oncology
• Cell Biology
• Immunology

Background:

• Polo-like kinase 1 (Plk1) is crucial for cell-cycle regulation and has been investigated as a potential biomarker for pancreatic ductal adenocarcinoma (PDAC) treatment.
• Clinical trials targeting Plk1 for PDAC have yielded limited success, highlighting a need to understand resistance mechanisms and Plk1's role in PDAC progression.

Purpose of the Study:

• To investigate the role of Plk1 in PDAC progression and its potential as a therapeutic target.
• To elucidate the mechanisms by which Plk1 inhibition affects PDAC and its response to immunotherapy.

Main Methods:

• Utilized an inducible transgenic mouse model with pancreas-specific Plk1 expression.
• Performed bioinformatics analyses to identify Plk1-associated regulatory networks in PDAC.
• Investigated the effects of Plk1 inhibition/depletion on PD-L1 expression, NF-κB pathway activation, and immune responses in PDAC models.

Main Results:

• Plk1 overexpression inhibited acute pancreatitis and delayed PDAC precursor lesions in mice.
• Plk1 inhibition or depletion led to PD-L1 upregulation via NF-κB pathway activation.
• Plk1-mediated phosphorylation of RB at S758 was found to inhibit NF-κB nuclear translocation.
• Plk1 inhibition sensitized PDAC to immune checkpoint blockade by activating antitumor immunity.

Conclusions:

• Plk1 acts as a suppressor of PDAC progression and inhibits NF-κB activity.
• Targeting Plk1 can enhance the efficacy of immunotherapy in PDAC by modulating PD-L1 expression and antitumor immunity.